Diren Arsoy

Dr. Diren Arsoy


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
PDF file
DADiren Arsoy
Diren Arsoy
MPMark W. Pagnano
Mark W. Pagnano
DLDavid G. Lewallen
David G. Lewallen
AHArlen D. Hanssen
Arlen D. Hanssen
RSRafael J. Sierra
Rafael J. Sierra
We observed isolated tibial component debonding from the cement in one modern primary TKA design (NexGen LPS 3° tibial tray; Zimmer, Warsaw, IN, USA). This failure mechanism is sparsely reported in the literature. We (1) assessed survivorship of this tibial tray with special emphasis on debonding; (2) described clinical and radiographic features associated with tibial failure; and (3) compared patient and radiographic features of the failures with a matched cohort. A total of 1337 primary TKAs were performed with a cemented NexGen LPS 3° tibial tray over an 11-year period. Twenty-five knees (1.9%) were revised for tibial debonding. BMI and radiographic alignment in the tibial debonding group were compared with a matched control group. Implant survivorship was assessed using tibial debonding as the end point. Survival free of revision from tibial debonding was 100% at 1 year and 97.8% at 5 years. The tibial failures shared a typical radiographic pattern with debonding at the cement-implant interface and subsidence into varus and flexion. We found no link between limb alignment or individual component alignment and failure because 22 of the 25 failures occurred in well-aligned knees. Our standardized followup of patients undergoing TKA at routine intervals allowed us to discover a higher rate of revision resulting from tibial debonding. We have discontinued the use of this particular tibial tray for primary TKA and surveillance for patients undergoing TKA continues to be warranted. Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

1 October 2014 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
DADiren Arsoy
Diren Arsoy
JWJessica A. Woodcock
Jessica A. Woodcock
DLDavid G. Lewallen
David G. Lewallen
RTRobert T. Trousdale
Robert T. Trousdale

1 September 2016 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
BCBrian P. Chalmers
Brian P. Chalmers
DADiren Arsoy
Diren Arsoy
RSRafael J. Sierra
Rafael J. Sierra
DLDavid G. Lewallen
David G. Lewallen
RTRobert T. Trousdale
Robert T. Trousdale

3 April 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
TBTimothy S. Brown
Timothy S. Brown
MTMeagan E. Tibbo
Meagan E. Tibbo
DADiren Arsoy
Diren Arsoy
DLDavid G. Lewallen
David G. Lewallen
AHArlen D. Hanssen
Arlen D. Hanssen
MAMatthew P. Abdel
Matthew P. Abdel
Background: Cementation of a constrained liner is a viable option for treating instability after total hip arthroplasty (THA) when the acetabular component is well fixed and well aligned. However, concerns regarding long-term mechanical failure and recurrent instability remain. The aim of this study was to evaluate the long-term survivorship, complications, and clinical and radiographic outcomes of constrained polyethylene liners cemented into well-fixed acetabular components at the time of revision THA.Methods: We identified 125 cases in which a constrained liner of 1 design was cemented into a retained, osseointegrated acetabular component during revision THA between 1998 and 2006. The mean patient age at revision was 70 years. Mean follow-up was 7 years. Survivorship data, risk of instability, and clinical and radiographic outcomes were analyzed.Results: Survivorship free from revision for instability was 86% at 5 years and 81% at 10 years. Survivorship free from aseptic acetabular component revision was 78% at 5 years and 65% at 10 years, with the most common failure mechanism being dissociation of the constrained liner from the acetabular component. Survivorship free from revision for any reason was 76% at 5 years and 60% at 10 years. The most common complications were instability and periprosthetic joint infection, with cumulative incidences at 7 years of 18% and 11%, respectively. Harris hip scores did not significantly improve. Cup position did not affect implant survivorship or risk of dislocation.Conclusions: Cementing a constrained liner into a retained acetabular shell at the time of revision THA has durable long-term results, with 8 in 10 patients free from instability at 10 years. Aseptic acetabular survivorship was worse (65%) at 10 years, primarily due to dissociation of the constrained liner from the acetabular component.Level of Evidence: TherapeuticLevel IV. See Instructions for Authors for a complete description of levels of evidence.

1 January 2016 in Bone & Joint Research
Verified
Journal Article
Open access
PDF file
JBJ. D. Barlow
J. D. Barlow
MMM. E. Morrey
M. E. Morrey
RHR. U. Hartzler
R. U. Hartzler
DADiren Arsoy
Diren Arsoy
SRS. Riester
S. Riester
MAMatthew P. Abdel
Matthew P. Abdel
Aims Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (sd) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties. Cite this article: M. P. Abdel. Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release: A biomechanical, histological, and genetic analysis. Bone Joint Res 2016;5:11–17. doi: 10.1302/2046-3758.51.2000593

1 June 2017 in Journal of Orthopaedic Trauma
Verified
Journal Article
Closed access
DADiren Arsoy
Diren Arsoy
MGMichael J. Gardner
Michael J. Gardner
DADerek F. Amanatullah
Derek F. Amanatullah
JHJames I. Huddleston
James I. Huddleston
Stuart B GoodmanStuart B Goodman
Stuart B Goodman
JBJulius A. Bishop
Julius A. Bishop
Objective: To evaluate the effect of continuous femoral nerve catheter (CFNC) for postoperative pain control in geriatric proximal femur fractures compared with standard analgesia (SA) treatment. Design: Retrospective comparative study. Setting: Academic Level 1 trauma center. Patients/Participants: We retrospectively identified 265 consecutive geriatric hip fracture patients who underwent surgical treatment. Intervention: One hundred forty-nine patients were treated with standard analgesia without nerve catheter whereas 116 patients received an indwelling CFNC. Main Outcome Measurement: Daily average preoperative and postoperative pain scores, daily morphine equivalent consumption, opioid-related side effects and discharge disposition. Results: Patients with CFNC patients reported lower average pain scores preoperatively (1.9 ± 1.7 for CFNC vs. 4.7 ± 2 for SA; P < 0.0001), on postoperative day 1 (1.5 ± 1.6 for CFNC vs. 3 ± 1.7 for SA; P < 0.0001) and postoperative day 2 (1.2 ± 1.5 for CFNC vs. 2.6 ± 2.1 for SA; P < 0.0001). CFNC group consumed 39% less morphine equivalents on postoperative day 1 (4.4 ± 5.8 mg for CFNC vs. 7.2 ± 10.8 mg for SA; P = 0.005) and 50% less morphine equivalent on postoperative day 2 (3.4 ± 4.4 mg for CFNC vs. 6.8 ± 13 mg for SA; P = 0.105). Patients with CFNC had a lower rate of opioid-related side effects compared with patients with SA (27.5% for CFNC vs. 47% for SA; P = 0.001). More patients with CFNC were discharged to home with or without health services than patients with SA (15% for CFNC vs. 6% for SA; P = 0.023). Conclusion: Continuous femoral nerve catheter decreased daily average patient-reported pain scores, narcotic consumption while decreasing the rate of opioid-related side effects. Patients with CFNC were discharged to home more frequently. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.